LBLeyla Bölek

Leyla Bölek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leyla Bölek has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Aslı Gelincik

    Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine Istanbul University Istanbul Türkiye

    1 shared publication
  • Ayşe Feyza Aslan

    Department of Internal Medicine Division of Allergy and Clinical Immunology Istanbul University Istanbul Faculty of Medicine Istanbul Türkiye

    1 shared publication
  • Bircan Erden

    Department of Internal Medicine Division of Allergy and Clinical Immunology Istanbul University Istanbul Faculty of Medicine Istanbul Türkiye

    1 shared publication
  • Derya Unal

    Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul, Turkey

    1 shared publication
  • Esra Kaya

    Department of Internal Medicine Division of Allergy and Clinical Immunology Istanbul University Istanbul Faculty of Medicine Istanbul Türkiye

    1 shared publication
  • Mehmet Emin Sezgin

    Department of Internal Medicine Division of Allergy and Clinical Immunology Istanbul University Istanbul Faculty of Medicine Istanbul Türkiye

    1 shared publication

Latest Publications

  • Open Access

    NSAID Tolerance Can Be Restored in NECD Even in the Absence of Complete Remission of Urticaria

    by Merve Hormet Igde, Pelin Korkmaz, Semra Demir, Osman Ozan Yegit, Derya Ünal, Merve Dilşad Atasever, Ayşe Feyza Aslan, Leyla Bölek, Selin Ece Güzel, Nevzat Kahveci, et al.

    Background/Aim: Data on the course of nonsteroidal anti‐inflammatory drug (NSAID) hypersensitivity in NSAID‐exacerbated cutaneous disease (NECD) are limited. We aimed to evaluate NSAID tolerance in NECD patients with well‐controlled urticaria. Methods: 142 patients with well‐controlled urticaria [Urticaria Control Test (UCT) ≥ 12; Urticaria Activity Score over 7 days (UAS7) ≤ 6] underwent a single blind, placebo‐controlled acetylsalicylic acid (ASA) provocation test. Patients were categorized into three groups based on their treatment; omalizumab, antihistamine, or no treatment. Results: The median age of the patients was 40 years (IQR 31.5–52), and 79.6% were female. The median disease duration of chronic spontaneous urticaria (CSU) was 4 years (IQR 2–8). The ASA provocation test was positive in 29 patients (20.4%). Positive patients had lower UCT and higher UAS7 scores (both p < 0.001). ASA provocation test positivity was more common in the antihistamine group compared to both the omalizumab ( p = 0.001) and untreated groups ( p < 0.001). ROC analysis showed that UCT ≤ 15 predicted ASA provocation test positivity with 72.4% sensitivity and 83.2% specificity, while UAS7 ≥ 4 predicted positivity with 72.4% sensitivity and 86.7% specificity. The negative predictive values (NPV) were 92.2% and 92.5%, respectively. Conclusion: To our knowledge, this is the first study to demonstrate, in a large NECD cohort, that NSAID tolerance can be achieved in patients with well‐controlled urticaria under different treatment modalities, regardless of complete remission status. UCT ≤ 15 and UAS7 ≥ 4 are useful clinical predictors of provocation test positivity and, given their high NPVs, are particularly valuable for excluding positivity.